TQT Study for BI 409306

Phase 1, randomised, double-blind trial of osoresnontrine in schizophrenia (15 arms), sponsored by Boehringer Ingelheim. Primary endpoints: Change From Baseline in QTcF at That Timepoint Where Difference Between 50 mg BI 409306 and Placebo Takes Its Maximum at 24 hours and Change From Baseline in QTcF at That Timepoint Where Difference Between 250 mg BI 409306 and Placebo Takes Its Maximum at 24 hours. Started May 2019; status: completed.